

“Excellent mix of discussion, panels and presentations. Very interesting topics”

(2009 delegate, PMPS)

# Biotech & Pharmaceutical Patenting

17th – 18th February 2010  
Hilton Munich Park, Munich,  
Germany

Protecting and exploiting medical innovation  
around the globe

13.5 accredited  
CPD hours  
available

**Benefit  
from the  
international  
expertise of:**



Sponsors:



**LOVELLS**



**DANNEMANN  
SIEMSEN  
ADVOGADOS**



**Don't miss  
this unique  
opportunity  
to:**



Media Partners:

- ➔ **Dr. Dieter Schneider**, *Head of Division*, **German Patent & Trademark Office** (Germany)
- ➔ **Peter de Weerd**, *Vice President & Global Head of IP Optimisation*, **Novartis** (Switzerland)
- ➔ **Naomi Pearce**, *Patent Director*, **Hospira** (Australia)
- ➔ **Marc Markus**, *European Biology Patent Lead*, **Pfizer** (France)
- ➔ **John Nevard**, *Chief IP Counsel*, **Inverness Medical** (UK)
- ➔ **Dr. Michael Kock**, *Global Head of IP*, **Syngenta** (Switzerland)
- ➔ **Dr. Frank Burkert**, *European Patent Attorney*, **Bayer Healthcare** (Germany)
- ➔ **Bert Oosting**, *Partner*, **Lovells** (The Netherlands)
- ➔ **Gustavo Morais**, *Partner*, **Dannemann Siemsen Advogados** (Brazil)
- ➔ **Simon Cohen**, *Partner*, **Taylor Wessing LLP** (UK)
- ➔ **Pravin Anand**, *Managing Partner*, **Anand & Anand** (India)
- ➔ **Pierre Véron**, *Founding Partner*, **Véron & Associés Avocats** (France)
- ➔ **Matthew Swinn**, *Partner*, **Corrs Chamber Westgrath** (Australia)
- ➔ **Dr. Benjamin Bai**, *Partner*, **Jones Day** (China)
- ➔ **Christoph de Coster**, *Partner*, **Taylor Wessing LLP** (Germany)
- ➔ **Dr. Jürgen Meier**, *Partner*, **Vossius & Partner** (Germany)
- ➔ **Adam Cooke**, *Partner*, **Lovells** (UK)
- ➔ **Kevin Mooney**, *Partner*, **Simmons & Simmons LLP** (UK)
- ➔ **Peter Klusmann**, *Partner*, **Hoffmann Eitle** (Germany)
- ➔ **Vladislav Ugryumov**, *Consultant*, **Lovells** (Russia)
- ➔ **Ken Adamo**, *Partner*, **Jones Day** (US)
- ➔ **Joaquim Goulart**, *Partner*, **Dannemann Siemsen Advogados** (Brazil)
- ➔ **Otto Swens**, *Partner*, **Vondst Advocaten** (The Netherlands)
- ➔ **Alan Johnson**, *Partner*, **Bristows** (UK)
- ➔ **Klaus Haft**, *Partner*, **ROKH IP** (Germany)
- ➔ **Ian Forrester QC**, *Partner*, **White & Case LLP** (Belgium)

- **Prepare for upcoming changes** with updates directly from the decision-makers at key patent offices
- Examine the effect of recent case law on **patent term extensions and paediatric data exclusivity**
- Increase your success in cases relating to **single enantiomers, biosimilars** and **second medical use claims** with a critical review of the latest decisions of courts around the world
- Update on latest developments in **DNA patenting** with insights from the agrochemical sector
- Overcome the challenges of **patenting diagnostic methods** now and in the future
- **Select your litigation forum wisely** with a comparative examination of litigation across Europe, the US and the BRIC territories

# BIOTECH & PHARMACEU

## CONFERENCE DAY ONE

08:30 Registration and Coffee

09:00 Chair's Opening Remarks

*Peter de Weerd, Vice President & Global Head of IP Optimisation, Novartis (Switzerland)*

09:15 **Keynote Critical Update: Patent Filing and Prosecutions: What You Need to Know!**

Hear first hand how recent and upcoming changes will affect your patenting strategy, with updates directly from senior representatives at the major patent offices. Come armed with your questions as you get the opportunity to ask for the answers you need.

*Dr. Dieter Schneider, Head of Division, German Patent & Trademark Office*

*Senior representative from European Patent Office invited*

*Senior representative from World Intellectual Property Organisation invited*

10:45 **Top Competition Law Concerns**

- The phenomenon of parallel trade and its legal status after GSK
- The implications of the Commission's sector inquiry
- Settlement of patent disputes
- Article 82 EC and abuse

*Ian Forrester QC, Partner, White & Case LLP (Brussels)*

11:30 **Patenting Single Enantiomers**

- Convergence of the decisions of the UK and German courts
- The approach adopted by the Australian courts
- Data exclusivity considerations
- Selection inventions

*Kevin Mooney, Partner, Simmons & Simmons LLP (UK)*

*Peter Klusmann, Partner, Hoffmann Eitle (Germany)*

*Matthew Swinn, Partner, Corrs Chamber Westgrath (Australia)*

12:30 Networking Lunch

13:30 **Patent Term Extensions and Paediatric Data Exclusivity**

- Legal opportunities for market exclusivity in the pharmaceutical field
- Patent term extensions in different jurisdictions
- Requirements for getting patent term extensions
- Case law related to patent term extensions

- Granting negative term SPCs in the wake of Merck
- Paediatric data exclusivity in light of the Losartan case
- Impact of ECJ's decision in AHP

*Dr. Frank Burkert, European Patent Attorney, Bayer Healthcare (Germany)*

*Bert Oosting, Partner, Lovells (The Netherlands)*

14:15 **Second Medical Use Claims**

- Kos case: Discussion of likely impact of the decision of the EPO's Enlarged Board of Appeal

*Adam Cooke, Partner, Lovells (UK)*

15:00 Networking Break

15:20 **Stem Cells Revisited**

- General overview on stem cells: The technology and its assessment before the patent offices - is the term "stem cell" clear?
- WARF and beyond: What do we learn from G2/06 and how do we proceed before the EPO?
- The British and the German View: Will the European Court of Justice bring the desired clarity?

*Dr. Jürgen Meier, Partner, Vossius & Partner (Germany)*

16:00 Panel Discussion: **Patenting Biosimilars: Global Perspectives from Industry**

- Navigating the strict regulatory hurdles to get products to market
- Comparing the approaches taken by the regulators in Australia, Europe and the US

*Naomi Pearce, Patent Director, Hospira (Australia)*

*Marc Markus, European Biology Patent Lead, Pfizer (France)*

*US industry expert to be confirmed - download the latest brochure at [www.ibclegal.com/biopharma](http://www.ibclegal.com/biopharma) for updates*

17:00 Chair's Closing Remarks

From 17:15



### Drinks Reception

Continue networking with new colleagues and old friends courtesy of Lovells.

Lovells

### Conference documentation is available:

If you are unable to attend, why not pass the brochure on to a colleague? Don't forget you need not miss out; the conference notes are available after the event for only £295.

### CPD points

Attendance at this conference will entitle you to 13.5 CPD hours from the Solicitors' Regulation Authority.

Bar Council CPD hours are also available, email [ibclegal@informa.com](mailto:ibclegal@informa.com) for more information

## CONFERENCE DAY TWO

### 08:15 **Breakfast Briefing: What is Going on in the Pharmaceutical Patents in Brazil?**

- Patent litigation – a new reality at the Brazilian courts
- Linkage – is it feasible?
- Data protection: A scenario
- Is the biosimilar a reality in Brazil?

Joaquim Goulart, *Partner*, **Dannemann Siemsen Advogados** (Brazil)

Gustavo Morais, *Partner*, **Dannemann Siemsen Advogados** (Brazil)

09:00 Registration and Coffee

### 09:15 **Chair's Opening Remarks**

Peter de Weerd, *Vice President & Global Head of IP Optimisation*, **Novartis** (Switzerland)

### 09:30 Panel Discussion: **Key Issues to be Aware of when Patenting Pharmaceutical and Biotech Products in the BRIC Territories**

- An overview of recent developments in the pharmaceutical patent area in Brazil
- The developing practice of post-grant oppositions in India
- The effect of the 3rd amendment on patenting in China
- Patent litigation trends in Russia - overview and recent developments

Joaquim Goulart, *Partner*, **Dannemann Siemsen Advogados** (Brazil)

Gustavo Morais, *Partner*, **Dannemann Siemsen Advogados** (Brazil)

Vladislav Ugryumov, *Partner*, **Lovells** (Russia)

Dr. Benjamin Bai, *Partner*, **Jones Day** (China)

Pravin Anand, *Managing Partner*, **Anand & Anand** (India)

### 10:30 **How to Protect your Innovations in Emerging Markets: An Industry Perspective**

- What can be done by Novartis in the BRIC territories and other emerging markets?
- How to cope with counterfeit products in emerging markets

Peter de Weerd, *Vice President & Global Head of IP Optimisation*, **Novartis** (Switzerland)

11:15 Networking Break

### 11:35 **Latest Challenges in Patenting Diagnostic Methods**

- Biomarkers
  - Where do you get them from?
  - Are they patentable?
- How are antibodies produced?
- What do you need to be prepared for in the future?
  - Telemetry: Remote access diagnostics
- Compare and contrast with procedures for patenting chemical inventions

John Nevard, *Chief IP Counsel*, **Inverness Medical** (UK)

### 12:15 **Inventor Compensation: A Comparative Approach**

- *Kelly v GE Healthcare*

- Jurisdictional approaches

Alan Johnson, *Partner*, **Bristows** (UK)

Klaus Haft, *Partner*, **ROKH IP** (Germany)

13:00 Networking Lunch

### 14:00 **Litigating Patents in Europe: A Comparative Viewpoint**

- Update on the move towards a unified patent court and the European Patent Litigation Agreement (EPLA)
- Are interim injunctions still always commercially viable in the light of *Smith & Nephew* and *Servier v Apotex*?
- Why are the national courts differing in their opinions?

- *Lundbeck*

- *Conor v Angiotech*

Moderator: Simon Cohen, *Partner*, **Taylor Wessing LLP** (UK)

Nigel Stoate, *Partner*, **Taylor Wessing LLP** (UK)

Pierre Véron, *Founding Partner*, **Véron & Associés Avocats** (France)

Christoph de Coster, *Partner*, **Taylor Wessing LLP** (Germany)

Otto Swens, *Partner*, **Vondst Advocaten** (The Netherlands)

15:00 Networking Break

### 15:15 **Litigating Patents in the US Courts**

- Developments in post-KSR obviousness / invalidity law
  - In *Re Kubin*
  - *Bayer v Barr*
  - USPTO guidelines/KSR application during prosecution
- Developments that may effect biotech and pharmaceutical patents generally
  - US Supreme Court *Bilski* decision
  - USPTO reaction to *Bilski*
  - "Stay away/stay out" provisions/ payments to generics
  - *Centocor Inc. v Abbott Labs* ("Humira"), \$1.7billion verdict (Eastern District of Texas) and the potential Federal Circuit treatment

Ken Adamo, *Partner*, **Jones Day** (US)

### 16:00 **No Performance – No Protection? Protection of DNA Sequences Under Directive 98/44/EC**

Implications of the referral to the European Court of Justice in the case *Monsanto v Cefetra*

Dr. Michael Kock, *Global Head of IP*, **Syngenta** (Switzerland)

### 16:45 **Question & Answer Panel**

Address any remaining questions you have on patenting in the pharmaceutical and biotech sectors to a selection of speakers from the 2 day conference.

Naomi Pearce, *Patent Director*, **Hospira** (Australia)

Peter de Weerd, *Vice President & Global Head of IP Optimisation*, **Novartis** (Switzerland)

Marc Markus, *European Biology Patent Lead*, **Pfizer** (France)

Matthew Swinn, *Partner*, **Corrs Chamber Westgrath** (Australia)

17:15 Chair's Closing Remarks

17:30 Close of Conference

# Biotech & Pharmaceutical Patenting

17th – 18th February 2010 • Hilton Munich Park, Munich, Germany

VIP CODE:

Please quote the above VIP code when registering

## WHEN AND WHERE

**KW8066**  
17th – 18th February  
2010

**Venue:** Hilton Munich Park, Munich, Germany  
Am Tucherpark 7  
80538 Munich  
Germany  
Telephone: +49 (0) 89 3845 0

Delegates are responsible for the arrangement and payment of their own travel and accommodation. Informa has arranged a special room rate for Informa delegates. If you wish to book a room, please contact Zibrant, call +44 (0)1332 285590; email [informa@zibrant.co.uk](mailto:informa@zibrant.co.uk) or visit [www.zibrant.co.uk/informa](http://www.zibrant.co.uk/informa). Please book early to avoid disappointment - some destinations fill up quickly.

## PERSONAL DETAILS

**1st Delegate** Mr/Mrs/Ms

Job title \_\_\_\_\_ Department \_\_\_\_\_  
Telephone \_\_\_\_\_ Fax \_\_\_\_\_  
Email \_\_\_\_\_

Yes! I would like to receive information about upcoming events by email. By giving you my email address I am giving ONLY Informa companies the permission to contact me by email

Yes! I would like to receive information about future events and services via fax  
Signature: \_\_\_\_\_

**2nd Delegate** Mr/Mrs/Ms

Job title \_\_\_\_\_ Department \_\_\_\_\_  
Telephone \_\_\_\_\_ Fax \_\_\_\_\_  
Email \_\_\_\_\_

Yes! I would like to receive information about upcoming events by email. By giving you my email address I am giving ONLY Informa companies the permission to contact me by email

**3rd Delegate** Mr/Mrs/Ms

Job title \_\_\_\_\_ Department \_\_\_\_\_  
Telephone \_\_\_\_\_ Fax \_\_\_\_\_  
Email \_\_\_\_\_

Yes! I would like to receive information about upcoming events by email. By giving you my email address I am giving ONLY Informa companies the permission to contact me by email

Name of your Line Manager Mr/Mrs/Ms \_\_\_\_\_

Job title \_\_\_\_\_ Department \_\_\_\_\_  
Telephone \_\_\_\_\_ Fax \_\_\_\_\_  
Email \_\_\_\_\_

**Booking Contact** Mr/Mrs/Ms

Job title \_\_\_\_\_ Department \_\_\_\_\_  
Telephone \_\_\_\_\_ Fax \_\_\_\_\_  
Email \_\_\_\_\_

Our statement of integrity can be found on our website at [www.iir-events.com/IIR-conf/PrivacyPolicy.aspx](http://www.iir-events.com/IIR-conf/PrivacyPolicy.aspx)

## COMPANY DETAILS FOR INVOICING PURPOSES

Company Name \_\_\_\_\_  
Postal Address \_\_\_\_\_

Telephone \_\_\_\_\_ Fax \_\_\_\_\_

Nature of Business \_\_\_\_\_

Billing Address (if different from above address) \_\_\_\_\_

Billing E-mail Address: \_\_\_\_\_

### Unable to Attend - Event Documentation

Nothing compares to being there – but you need not miss out!  
Don't delay and order your documentation today  
Simply tick the box, complete your details above and send the form along with payment.  
We regret Documentation Orders can only be processed on receipt of Credit Card details

**Biotech & Pharmaceutical Patenting - £295 (no VAT)**  
We regret documentation orders can only be processed on receipt of credit card details

**Data Protection** The personal information shown on this form, and/or provided by you, will be held on a database and may be shared with other companies in the Informa Group in the UK and internationally. If you do not wish your details to be available to other companies in the Informa Group please contact the Database Manager at the above address, Tel +44 (0) 20 7017 7077, Fax +44 (0) 20 7017 7828 or email: [integrity@iirtld.co.uk](mailto:integrity@iirtld.co.uk)

Occasionally your details may be obtained from, or made available to, external companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box

## FIVE EASY WAYS TO REGISTER



### Telephone:

Tel: +44 (0)20 7017 5503  
Please remember to quote  
KW8066



### Mail:

this completed form  
together with payment to:  
**Nicola Rogers**  
Informa Customer Services  
PO Box 406, West Byfleet  
Surrey KT14 6WL, UK



### Fax:

Complete and send this  
registration form to:  
Fax: +44 (0)20 7017 4746



### Email:

[professionalcustserv@informa.com](mailto:professionalcustserv@informa.com)



### Web:

[www.ibclegal.com/biopharma](http://www.ibclegal.com/biopharma)

Payment should be made within 14 days of registration. All registrations must be paid in advance of the event.  
If there is no VIP code, please quote KW8066

## HOW MUCH?

### Register by 4th December 2009 - SAVE £200

	CODE	PRICE	19% MwSt	TOTAL PRICE
<input type="checkbox"/> <b>Biotech &amp; Pharmaceutical Patenting</b>	KW8066	£1,299.00	£246.81	£1,545.81

### Register by 15th January 2010 - SAVE £100

<input type="checkbox"/> <b>Biotech &amp; Pharmaceutical Patenting</b>	KW8066	£1,399.00	£265.81	£1,664.81
--	--------	-----------	---------	-----------

### Register after 15th January 2010

<input type="checkbox"/> <b>Biotech &amp; Pharmaceutical Patenting</b>	KW8066	£1,499.00	£284.81	£1,783.81
--	--------	-----------	---------	-----------

Savings include Early Booking Discounts. All additional discounts can only be applied at the time of registration and discounts cannot be combined. All discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs. **£200 discount for 3rd and subsequent delegates.**  
The MwSt rate is subject to change and may differ from the advertised rate. The amount you are charged will be determined when your invoice is raised.

## THREE EASY WAYS TO PAY

- Cheque. Enclosed is our cheque for £ ..... in favour of Informa UK Ltd  
Please ensure that the Reference Code **KW8066** is written on the back of the cheque
- Credit Card. Please debit my:  VISA  AMEX  MASTERCARD  DINERS

Card No: \_\_\_\_\_ CVV Number: \_\_\_\_\_

Expiry Date: \_\_\_\_\_

Signature: \_\_\_\_\_

please note that credit cards will be debited within 7 days of your registration on to the conference

By Bank transfer: Full details of bank transfer options will be given with your invoice on registration.

**Incorrect Mailing** If you are receiving multiple mailings or you would like us to change any details or remove your name from our database, please contact the Database Manager at the above address, Tel +44 (0) 20 7017 7077, Fax +44 (0) 20 7017 7828 or email: [integrity@iirtld.co.uk](mailto:integrity@iirtld.co.uk) - quoting the reference number printed on the mailing label.

**Additional Requirements** Please notify IIR at least one month before the conference date if you have any additional requirements e.g. wheelchair access, large print etc.

**Cancellations** CANCELLATIONS confirmed in writing (letter or fax) more than two weeks before the event are subject to a service charge of 10% of the conference fee, + MwSt. Should you cancel one week before the event then the service charge rises to 50% of the conference fee +MwSt. Regrettably, the full fees remain payable for cancellations received less than one week prior to the course. A substitute delegate is welcome at no extra charge.